Agios Pharmaceuticals gets PYRUKYND FDA approval for hemolytic anemia
Agios Pharmaceuticals has secured approval for PYRUKYND (mitapivat) from the US Food and Drug Administration (FDA) for the treatment of hemolytic anemia in adult patients having pyruvate kinase (PK) deficiency. PYRUKYND is an oral pyruvate kinase activator, which is now the first approved disease-modifying therapy for the rare, debilitating, lifelong hemolytic anemia. The FDA approval […]